

Lonza

Dr Moncef Slaoui

Dr Moncef Slaoui brings to Lonza extensive experience from his career with GlaxoSmithKline spanning nearly 30 years. In this time, he held a number of leadership positions, including Member of the Board of GSK PLC, Chairman of Pharmaceutical R&D; and Chairman of Global Vaccines. Currently, Dr Slaoui is partner at Medicxi, a venture capital firm specializing in seed, Series A, early stage and late stage life sciences investments; he also sits on various biotechnology companies' boards. Dr Slaoui received his Ph.D. in Molecular Biology and Immunology from Brussels University in 1983. He later received an accelerated Master of Business Administration from IMD in Lausanne (Switzerland) in 1998.



Current activities and functions

Public Company Board Mandates

- Independent Member of the Board of Directors of Moderna (since 2017)

Further Mandates

- Chairman of Monopteros (A Medicxi Company) (since 2018)
- Chairman of Divide & Conquer (A Medicxi Company) (since 2017)
- Chairman of Sutrovax (since 2017)
- Chairman of Galvani Bioelectronics (since 2016)
- Chairman of Clasado (since 2017)

Activity

- Partner at Medicxi (since 2017)

Former Activities and Functions

- Member of the Advisory Board of the Qatar Foundation (2009 - 2020)
- Member of the Board of Directors of International AIDS Vaccines Initiatives (2015 - 2017)
- Member of the Board of GSK PLC (2006 - 2017)
- Chairman of Global Vaccines of GSK PLC (2009 – 2017)
- Chairman of Global Research & Development of GSK PLC (2006 – 2015)
- Various leadership roles in Research & Development including Worldwide Business Development & External Alliances for GSK PLC (1988 – 2003)